ADMA Biologics (ADMA) 10 Nov 222022 Q3 Earnings call transcript

Good afternoon, and welcome to the ADMA Biologics Third Quarter 2022 Financial Results and Corporate Update Conference Call on Wednesday, November 9, 2022. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request and will be available on the company's website approximately 2 hours following the end of the call. At this time, I'd like to introduce Skyler Bloom, Senior Director of Business Development and Corporate Strategy at ADMA Biologics. ahead. go Please

Adam thank Financial discuss and quarter joining this BioCenters. Executive today us and Officer; Chief Welcome, Brian and and Biologics' you General financial to Lenz, by joined I'm ADMA corporate President, third President results afternoon and recent Executive Chief everyone, Vice updates. for Grossman, Officer for XXXX ADMA the Manager,

an an overview provide update Adam the today's will some Brian introductory will and then call, quarter provide corporate on third provide of progress, company's results. XXXX and During comments financial

corporate before Adam up today, on available provide Finally, release XXXX achievements then some at updates. will website a our recent and issued call brief detailing Earlier The summary questions. release results remarks third quarter certain financial opening is for the www.admabiologics.com. press the summarized we and

release begin will we Safe statements that SEC, All such or this our under results Before Private constitute subject events, forward-looking you comments, today's be statements press risks, and statements. the any Harbor from or factors, uncertainties the which call to as which making the formal the may XXXX. materially beliefs company's Act we Litigation those remind call of assertions cause in Securities the intentions, the expectations purposes during filings future represents by differ I'll today's that to with such in Reform provisions detailed our expressed implied of and are announcing concerning actual for forward-looking results forward-looking

discussion release the laws. except of issued to to we section as representing We any any refer statements not be date disclaim earnings year the views today our XX-Q ended section well as December factors XX-K XX, our notice Form as the required should such for this statements September the annual ended turn of actual materially important you Grossman. a risk over call of our to statements. from represent on obligations in report would the like the in the section for of Factors for federal addition, that our upon to of could as any specifically as Adam quarter With Risk securities call by and the subsequent XX, views as on results forward-looking XXXX only that, these now disclosure our We Form XXXX Adam? to any differ In factors I XXXX forward-looking date. relied of report cause quarterly update

afternoon, thank XXXX delivering everyone of performance of us company's for believe with Good record Skyler. objectives. We our We you, speaks to we as ADMA’s and hope strong safe. look remains to healthy you prospects third and ADMA’s and multiyear everyone, and strategy successful joining our Thank In today's quarter track our compelling execution call. on beyond. keeping on our demonstrates

evolving product to We million company growth financial third accelerate generate now approximately full now the raising of mix, $XXX company provided. the are again the coupled be $XXX of expects for favorably to quarter a with expectations total foundation year-over-year increased from pleased for million, believe XX% the The revenue towards year We strong previously profitability. establishes XXXX. revenues to

able throughout The growth belief barriers new revenue ASCENIV Brian third of will that demonstrate regard messaged. account for quarter. of have as related is ASCENIV. body and mix physician quarter XXXX better COVID to truly for to year the profile. visibility have provider pandemic for XXXX impacted product throughout ASCENIV historically our evidence to As [indiscernible] of Elevated will a the in to greater continued and to pathway profitability now We patient grow we our the unique have ability overall persisted launch quarters into opportunities Due expect been trends and the the XXXX throughout we well the coming rapidly continue demand detail, detail which illuminate to of will increased gives ASCENIV robust ultimately, our product a us confidence and the to throughout successfully portion commercial product believe we the fourth than engagement, we initial thereafter. positioned

quarter, build growing internal first the needs the coming year peak medical account immunocompromised we clinical on strategy, the during and as of the education launch conference infections upwardly a targeted new To opportunistically close, opportunity. a revise for enthusiasm overstated rapidly trajectory trajectory, we launch growth and in host. cannot mobilized identifying expected and third product's With ASCENIV our to be ASCENIV to our forecast the symposia respiratory managing

We Week, standing including only are quarter, and Disease resoundingly reception IG growth experts with the Society, studies in capacity is experience ASCENIV meeting. of these & discussions life strategy at feedback standard the importantly, to of full immunodeficiency. Anecdotal National told, the are benefits ASCENIV quality days initiatives regional product's of report and Immune demonstrating the are borne on Allergy that immunodeficiency the Globulin met this attendance strong medical at poorly and clinical disease improvements. Perhaps for Florida we All of being Also and were we were products. oftentimes ASCENIV and of we presented with Infectious patients being immunology in real patient area controlled including potential. recognized early successfully risk out primary patients in problematic significant believe the affairs world by positive remains market and a is believe national pleased nationally treated our and Asthma case world commercial most population Immunology symposia transplantation, Society primary real and during meetings, of medical infectious with

aims to potential ADMA commercialize name the and to that infections. company's population. amongst utility that high risk that with We that people, deficient exclusively vaccine ADMA we excited and success adverse physicians, the of product for deficient target in patients for patients. the our broader now RSV believe products many limited confidence by compromised serve trust providers immune synonymous is for is are scientifically is patient population although risk prospects a believe immune supports immune Additionally, reality population, this vaccines have It this approval to offense. with the primary unfortunate patients devotion is at Biologics we our validates novel and and It fuels our mission underserved us population,

amongst we reputation than during clinical ADMA for faster third an believe the studies in in this products. studies Additionally, need post and FDA prove population. the be date, ongoing BIVIGAM products primary include has and participating both enthusiasm have To its this the expand to ASCENIV. unmet BIVIGAM the requirement the We aged marketing investigators quarter, our deficient pediatric advanced products If speaks we established investigator indication been enrolling and notable well the trials of the are for anticipated and excitement potentially market immuno for pediatric and to patient provided successful may patients. the both indication will to authorization,

Turning to BIVIGAM.

Our near BIVIGAM term growth the demand building. product highs third confidence and through in end the X.X% record market quarter, and has that continued reached in during reports rapidly trend Biologics share ADMA’s now market suggest driven ADMA revenue longer as well gains. U.S. pull IG Various X% the market. to growth term market IG end a is growing share established industry as by

growth. anticipate patient the committed care. continuity continued as forward, ADMA to remains gains of structural IG well Moving we market share delivering from as tailwinds

to expanding supply our Our supply basis plasma center robust our of This portfolio. on navigate result which local assertive in value end the more flexibility ADMA be plasma ADMA our promises. our dedication plasma goals built, supply strong and BioCenters. for are communities commend help With commitments for in have so you from $XXX favorable to position pressures our excess donors operating have built total IG will and forward business the to entire Particularly at consumer challenging inventory we now is secure to historic stockholders to of plasma for monetize our ADMA to together dedication trend on this bound, ADMA’s remuneration who without upper forecast entertain the improving internal to in a on successfully to to team third forward. and the has third-party included date partner manage procurements plasma and of serve revised collection the know when support with the counting by conditions. normalized strong $XXX believe cyclicality hard across in further revenue trusted million in focus state-of-the-art moving anticipated execution significant work industry, These believe for to will chain across million in which for counter we to important many whom provide parties in external delivering we routinely request have our we economic plasma of the respect the We advisors. inflation that position could made is continue and conditions, we supply proud us. the healthcare believe measures we quarter team positions addition increased and plasma to network total recorded your as on focused the hyperimmune inventories, between and plasma forecast We rapidly of Thank can efforts management's we welcoming offset ongoing the plasma patients, inventories more due ahead. the accomplishments possible macroeconomic to leadership We these accelerate million to continue an to creating. donation rates. $XXX company look been is RSV contracts. supply are efforts patients, we achieving the BioCenters we normal the the achieved your in staff, have We backdrops source prescribers not the and upwardly to will and of are inventories and It the inherent donors opportunistically third context all the corporate periods financial including

to corporate before opportunities Brian, priority. our ongoing confirm turning and the alternatives creating over value top call a of to exploration remains I process strategic like is the would Additionally,

to of to I'd materialize. call third the update as quarter a over will the turn market We XXXX for developments now review Brian that the financials. With said, like

Adam. We the today highlights. press results. earlier I'll outlining some now of issued financial key discuss quarter a release third you, And Thank our XXXX

during XXXX This revenue $XX.X impacted ramp mentioned to both quarter and of customer the million favorably million $XX.X earlier, growth for our compared the compared IVIG our BIVIGAM quarter for quarter base of the or September were ended for The increase third to XXXX ASCENIV. of revenues third of commercial Adam and portfolio of approximately the by product expansion XX, continued of the was XX%. third up $XX.X represents quarter As XXXX. as third an XXXX million total

we and now execution, a guidance year to revenue provided. million the we million, of for from $XXX generate total As the full expect of result year revenues our up recently raising time second total most year-to-date are XXXX $XXX as this

compared profit during by our the contribution quarter realized of was XXXX. million profit for a million During Gross third $X.X margin ASCENIV. of gross from to of gross a the a XXXX, profit third ADMA quarter product quarter of favorable higher third the driven $X.X

are XXXX BIVIGAM quarter revenues depleted ADMA of during margin the favorably coming to scale note and product scale Encouragingly, our pleased lower it approved are X,XXX was is X,XXX quarters and product XXXX. the a produced product. liter scale X,XXX to at liter been was scale future we developments legacy portion scale lower half sold at that X,XXX produced exclusively has the significantly profit process, anticipated produced liter underlying of a the producing second production FDA important over which the compared manufacturing liter to since the margin third during evolving batches. by of with our fully Although, residual The liter X,XXX is inventory consisted to substantial X,XXX BIVIGAM the yields liter expected This mix, the to improve. margin be once and the subsequent of margins

XX% gross would Excluding for quarter lower have approximate to dynamics the margin associated to gross approximately the in the liter to quarter. compared the the the reported corporate third X,XXX of X% been higher with company transient margin margins a impact corporate gross results, margin Accounting midpoint. for to X% $X.X million XX% an sale to translating estimates scale normalized at approximately BIVIGAM, amounting

quarter diluted quarter, quarter loss $X $X non-recurring to the estimates the compared million XXXX quarter during and loss million Net profits company have net addition to approximately would debt XXXX increase the In Consolidated approximately September $X.X well XX% $XX.X $X.XX per incurred as a principal of the improvement by year's million interest loss approximately offset operating third $X.XX basic ended million basic XXXX. or expense approximately equivalent in of million to third for by for primarily $X.X prior the as to quarter. of to in loss additional third was been share operating million XX, interest compared expenditures the of quarter ended result per gross rising million attributable the or XX, rates. a diluted consolidated September higher net of share a and $XX.X compared $X.X as decreased

the Additional revenues to during $X.X we ahead We general and increased included gross forward in of operation the of to offsets doing grow was the administrative profitability to last marketing and well having year, anticipate become of pathway increasingly million centers will plasma plasma operating five quarter operating from on period third expenses increased and same and coming in nine our resulting as losses XXXX $X.X to to during profits as this headcount, centers center quarters. so, we increased net narrow attributed compared as million look quarters trends expanding to and continue expenditures. these clear. the in expect In expenses commercialization

the of non-dilutive an access additional and at strengthened stands pro a million approximately XXXX. total of and is at basis, through Accounts On $XX which forma have company's current receivable over discretion at equivalents March million liquidity of our cash approximately in our of recent $XX includes balance and cash approximately We quarter million to funds end funding the periods. sheet $XX which million. Hayfin, position from accessible the $XX third

total inventory as receivable September ADMA's well total as was $XX XX, our approximately asset at million of cash million. XXXX, of $XX $XXX and cost this notably approximately is approximately million and including million value of recorded accounts cash in $XXX equivalents As approximately

Lastly, operate segment, call now with of expansion the BioCenter unit we we approvals are FDA the plasma now year-to-date. segment our our collection received very BioCenter licensed four FDA pleased progress Through seven track FDA anticipate is with having present, on point and construction. source at centers plasma I year over are At our preparation remarks. material with collection additional presently which collection of facilities and ten traffic all operation two have under licensed supply raw considerably the With XX and facilities currently remain in are licensing turn now under our exceeding We donor end volumes, are Adam which we collection our collection having next to levels. will that U.S. plasma now to we by FDA in review, plasma plasma encouraged which that, closing foot the the with organization's pre-pandemic and back for facility, collecting self-sufficiency.

well you, ADMA established during on Thank foundation Brian. is XXXX. positioned build the to

we pieces landscape. have long XXXX one pleased as continuing our sustain to commitment is profitability to are month end forward XX provides Globulin are lead momentum its looking donate as to help now you as are this And forward profile forward look presently gives possible. up rapid and will we the seven longer to reaching quarters. that, revenue best-in-class make for we friends, open investment products for year revenue and in and to ADMA's year operator. growth deliver year's our staying helps strong efficacious like financial We in like Please provided top into lives a this to operational our by stockholders we on XXXX. term bottom your help term safe the In coming clearly to fastest with ADMA be of closing, commitments plasma And and thank your call to mission I the are the continuing with deliver results continued in the within unlocking, The neighbors. on advancement to we'd efficiencies that support remains market our sector. and comprehensively questions. you, defined and visibility growth our your and rapidly into to us Back towards End standing growth that guidance. expect and our in further insights lives. proud XXXX. reiterate power We for that company's pharmaceutical The previously It and of high time unique advance that and profitability. company's ADMA would The vein confidently for near successful this as to family growing for save enter and Immune considering all line the segments we place look demonstrated the and quality, manufacturing save

[Operator session first from conducted question-and-answer be question Group. comes Instructions] will electronically. Anthony Our with Today's Petrone you. Mizuho Thank

proceed. may You

Hi, Anthony.

on Anthony, if line is please unmute. your mute,

Hi, Adam. Hi, Hi, Skyler. Brian. that. for Apologies

quarter to and really culmination for lots just and the appears really of and milestone pandemic. the First of the the off, heavy on work be through a what congratulations hard company team, lifting

to team and congratulations in the So Maybe… everyone ADMA.

Thank you.

doing job, Just Anthony. our

update just the begin, in with of seems of the great to Adam, be to stable. plasma it COVID-XX, on a We're state across Maybe would demand start IG the general affairs endemic phase space.

However, kind where the back chains from pre-pandemic. we that are of way clawing improving, were still but are supply still

across your demand level? So trends maybe of supply I'll trending ups. end you center just a see follow at just have a year? the plasma, then views on infusion few the quick And update state into then affairs on of IG the And latest the where

Anthony. question, the for Thanks

healthy. there. of that side and in reiterate I weeks Plasma couple strong. comments an and collections improvement of brethren made companies out in the recovery I start is at We're over some our IG remarks. to with the that border. heard the The the I on out business you've The think prepared uptick the think seeing is collection last

not continued that's to and seven right and XX seeing throughout People a pull that but we're I our got our this weekly BIVIGAM it can't the and more patients the been engagements institutions. our going the calls that to think the seen the think continuing and stick? business. that to is utilization production in last is can prescriber incredible. to speaking a that on ASCENIV only ‘XX doing business patients. remainder shareholders. portfolio, months’ in do growth, there is how throughout we're durable. broader the we supply more are the about know of something the time do expect there quarter. Ultimately, we I to there. I beyond. BIVIGAM continue you certainly this quarter-over-quarter benefit I fourth other schedule the I through this this with see We've And with understand. our well, pertains and about year to a number not some ADMA that we've and especially all job is can out great being quarter in sticky. for in, as speak conference I we as record is you our IG I tell that of been ASCENIV speak know I it's know pushed with months because one-on-ones both asking, is shareholders being that horizon the you our some year We're trend How the blip cycle our It's added as products. have supply or into manufacturers infusion that and We've over issues and product the the ultimately know be will utilization is mean, sticky. and

pretty feeling So good. we're

ball last but cloudy, of to maybe Just has historically on typically it's part and crystal demand question, predict outpace your my supply. certainly your touch hard

see be collections start demand is finished process supply and think product before. There's think, that more to And going even than up while, ever a positivity got balance. there work be pent we've goods I fulfilled. It's sitting in in the around to I to until So starting we that with improving.

inventory and continuity As the we're the you and got challenges to of the strong hand. see care And meet we've supply with number on there. going ensuring we're the

going profits and grow line, and gross losses forward. narrow we're So going to increase hit milestones to top hopefully continue our

bit on to have the and ASCENIV, on I'll But I'll a And when ASCENIV stay initially then on company, we level little shift utilization ups. and at of revenue follow great. maybe Brian to pivot didn't couple out That's we a consumption. modeled of I'll One, this margins.

secondary on little the we're on I'll much time. margins. So coming bit is maybe primary seeing utilization RSV have one a ASCENIV that heightened How last from and in right And immune deficient versus the now season patients. demand follow-up real

broken we We that for marker know we quarters. of I record said couple do you RSV calls, I is we these any products an we not We're our promote want company. missed RSV RSV. here. a RSV I've this don't blend unique to to of through use sound to panel our So of has not for a platform it before. but hyperimmune, pathogens. the on like like you know, has various using antibodies this XXXX. that this source viral to who hyperimmune see RSV screen as IP And create plasma normal to and donors high-titer a IG respiratory ASCENIV with protection in we make

last majority during So accelerated helping you when patients render into going clearing they have call, deficient and about of there a sort the around other They've has out there's the may conversations infections prescribers. have of and this increases. these that is that and the bronchiectasis. population. got ASCENIV believe factors that you not overwhelming here we're medical that therapies. comorbidities as say take to The are it's in certain that setting. the I coming and And COVID But of primary awareness immune chronic differentiated that's they their not patients bacterial a really infections. outpatient COVID And Immune in they utilization chatter are with bouts that labeled a otitis, truly persistent the utilization. patients conversation and a of other benefits ASCENIV immune And These care risk that time is failed of It's Globulin problematic. and patients there care I the the limited. patients, pneumonia ASCENIV bit, They've them patients. had socioeconomic are These Internet and be have these majority harder hospitals, have I to quarter susceptible to I'm their dose the for education ASCENIV, are These awareness the in sinusitis, think business, that some deficient IG of sit own have but use acute engaged think said, pandemic in had multiple to dig about also to drive and hands. little drive really the out I more

to So in this as utility a as need vaccine. a know, premature would in or of and developments in no absolute for for be order that the said remarks, you But we've starting a it our in Are where for and to by was we encouraged back Whether community born prepared And excited one available. compromised about immune RSV I also the from for and ADMA had vaccine the nothing very community. passionate competent think Biologics products. infant, medical the or from passions the the the benefit to be we're the this patients the think I should there's reasons system win patients And immune not share me there the utility limited vaccine business is typically all respond I in day. an to I antigens vaccines. my these it

forward what it's for is and we're I And immune that compromised. doing really anything promote product for don't it special other and here. growing. for utilization something the we're the So is than peg indicated really moving the Anthony we Again, feel

to much there. that the congratulations walk on updated of just to just profits, coming guidance then looking XXXX to last outward much dynamics timeframe call intrigued pools transition everyone. leader leverage say, That's Again, maybe by of general How and the through in the mix should and a here from me for Brian shift so excellent. XXXX one expanded And I the is us net, for net margins, How high level is gains. to certainly just a And ASCENIV?

Thank you, acceleration Anthony, remarks. margin our ongoing with congratulatory be encouraged gross to of do We development. continue very for our the

launch BIVIGAM in mix XX-XX with when year our a really our seeing XX-XX, products, XX-XX. now XXXX, higher evolved margin are XX-XX, thinking were and back XXXX earlier initial about has We we XX-XX, from which a projections

really that's earlier. So year occurred a about

deplete further our liter produced X,XXX were margin continue to these and a batches, batches as So BIVIGAM year remaining ago. we our about of lower

seven As in month X,XXX you single to which the margins the approved mid-XX% from was coming XX% over to a production will understand, margin XX from XXXX to X,XXX go the the for low timeline, batches recently in BIVIGAM manufacturing X,XXX the gross batches liter double-digit scale, to these April quarters. margins

As margin, we've ASCENIV know, process, batch XX%. XX% are exclusively producing BIVIGAM. for higher already gross we're a more And you production near yields, as efficient stated only margins X,XXX between and

So looking gross couple next going in grow to of forward the we see beyond, forward to the future -- look continued margins into expansion. and continuing and quarters gross profit

Thank you.

Thank you. One moment for questions.

Our next question Raymond comes from with James. Elliot Wilbur

proceed. may You

Elliot. Hey,

afternoon. Good Thanks. Hey.

afternoon. Good

Good afternoon, Elliot.

fair terms the in inventory sounds the but math remain to X,XXX a the inventory is because about of couple completed I the just sense P&L. JV production the the the X,XXX liter mid-XXXX? of enter batch be that of the peak exhausted lower thinking in quarter the in I through margin And right respect say around, between pretty that But it run around and probably liter X,XXX it's quarter, the residual gross about next think clear question it am of till of fully impact having equation to want seems all is ever dynamics And the liter using guessing, I'm like or with this does quarters this over just sort there's the capability want to that going dynamics follow-up to mid-XXXX. to probably volumes, term, longer X,XXX margin the essentially ask some sort will production again production then capacity. liter by X,XXX

just Do question. that liter X,XXX The we is I'll the scale? It's make take No. of approved. want Maybe to that product at scale part approved.

are may want hyperimmunes. make other There future. that products in we to have We other the

we you expanding potential CDMO As know, opportunities. are our

been to in produce making you that of the different forward, the the plans have So no especially. that that additional are have going we have want various ‘XX, going just BIVIGAM qualified X,XXX question to any forward. BIVIGAM But at part July scales Elliott. scale we hit BIVIGAM validated liter Since of approval at and exclusively and scale

off meat of question. Brian the shut and I'll answer Now let the

Thank for the you, congratulatory Elliot, well. Thank you. No. again, remarks as

There's So produce already couple answer that the of X,XXX a of sold majority the meaning XXXX couple quarters sold process remaining range batch the that XXXX the the or by margin question, production for quarters starting batches next we X,XXX be to a throughout on, in middle the substantially liter the call XX% the X,XXX until will feel XXXX. the in X,XXX completely we've date. be we sold to middle be process. There's to expect it, sold depleted to middle XX% that higher up specifically spot the production liter of of of will exclusively your again at go of you're to

left. is lot year. think Brian I of There's a not the inventory right. last It but may It of middle could into accelerate, the Elliott,

obviously… would Which Okay.

Go ahead.

Sorry.

we gross go I which go continue level to to into the would that as to beyond a just margin was to we higher No, going -- corporate XX% margin. XXXX to XXXX continue to to corporate say XX% overall obviously and gross overall as accelerate get

ASCENIV out its that population. studies marketplace. take populations. they're don't or of like And all impact. not some to just question sounds of if over kind Thanks. on in It's an and RSV not wondering have you outside whether going months to actually population an lot stands still at are Okay. follow-up in Adam, of lot noise underway emergence different I'm that divergence just XX vaccinations including obviously the the the is XX a immuno general, in of landscape. But impact broader not. specifically sure the product, looking of pool. some data ask around take could RSV the not or of the own commentary based larger want But of evacuation impact donor a space your maps vaccines these Then to compromised next eventually In the I in the therapies the that somehow really on I'm your a earlier coming have be more on

RSV. about think we're RSV general COVID, ASCENIV yes, antibodies looking the I like be. of there Sure. interesting think with there's with I in there and is just textbooks, assay have targeting would There we of that's different people array high But question great pathogens. the be population mean, time. our marker all taters would that again, for a XX% are I RSV donors plasma? vaccine what's for hypothetically, proprietary the these patented and That's widespread the And an population levels when that it's to we donors. vaccination are identify not about that was immunology something in are and high we Again, high of are roughly viral about using In considered to responders. high who bacterial to they're wide responders microneutralization a a these feel that

RSV deficient generated So reiterate, patients to that They're responders the patients, the primary a that are naturally It's immune that antibody of deficient in for to for monoclonal the about in we're high naturally long is excited I've markets we the than RSV drug been from are is for late-XXs. different how and organ They're These antibody, in noise deficient from that immune vaccine a in scientific have from or perspective. a to donors full that a high cancer. the on time. slightly active immunosuppression. immune involved way a a is the being system hyperimmune noise is in immune unique in this bottle is Again, drug world, healthy Wherever occurring truly titers since is in on the system. utilized they the bone standpoint They the ASCENIV manufactured we support antibody blend transplants. drug IG stop. a think plasma. of population. have may have where secondary That's normal used periods it. are looking had about for chemotherapy. marrow again, It's patients. world, ASCENIV The a immune

any all that general. these So tell don't the I ASCENIV. is there's certainly think And impact this think on an companies. me in don't impact IG exciting space extremely I that watching any rooting time. for can scientists in you there's is and I on the

and why I pharma we as in And pretty think successful, that's ADMA. morning will And that these in sure lot I'm folks the that's less here people up a that if get why ultimately, at biotech all are of prove products up get die. well.

So exciting times. it's

Thanks.

question. Just one quick additional

volumes. earlier to spoke in trends You collection

maybe more in sort you Thanks. you're whether of just inflationary of seeing systemic environment could speak not et if impact collection more on pressures cost and volumes specifically terms to cetera.? general based collection wondering competition Just a macro costs or of of the and/or actual donor

we've just year-over-year and obviously, our collections to pleased collections. the centers, very with made with Well, progress about Elliot. we're our talk Thanks, Sure.

this approved three we and growth center have time had At seven. year. plasma FDA we last Our this now approvals centers, FDA year,

the staff. our thanks So so a year dedicated FDA had far. to tremendous and We've

last our have RSV and year construction. We centers center currently we XX Plasma, and have this collecting opened in nine five is NSP time now

the near in of donor again competition donor process fees some decreases down historic that come to and fees. to months. starting manufacturing stabilizing. to a Regarding decline high They locations, are seen Again, we're other all located areas are we've a ours. fees, seeing some is recall bit starting seven on XX our donor stabilize In from centers based

be which economy. donor higher fees decline, will adjusting reflected subsequent that even sell downwardly still global next donor other completed remaining previously our centers, regarding to it construction the -- the end of with continue and we FDA our those our those should we produced to and our remain costs, in have seen production lastly months, the as across disruptions collected and into XX internal centers issues fees they'll chain expect supply track the or costs XXXX, the plasma XX three So be be by our within a timelines that recently seven and improve. that been margin factored approved to on product to having were have to meaning And centers be

we've very centers. how with we're So come our proud of far

for you. moment Thank questions. One

comes Our Fitzgerald. Kristen Cantor with next from Kluska question

You may proceed.

Good Hi. everybody. afternoon,

add also on Let my you to this me quarter. congratulations

Thank you.

course. Yeah, of

revenue the really thoughts is So of years. in built heading you're outer products. here on I peak enthusiasm, mix growth How your opportunities around trends reiterated print calculations that into next time? quarter-over-quarter the and your of in this the at that year those seeing you saw But this the into based much on

great it's I a question. -- mean, Well,

seven can Kristen, business, about my year. know how I cycle, I capacity by that last our much made plant start the saying to think of And is. XX interesting we what off this we with I month what's production is also know

this, that make. a So look when at finite amount of we can we there's product

know XX% going have amount could that the our about we critical patients to ball mass. BIVIGAM that don't alluding what XX-XX have IG margin network continues a our of center diseases, Now from products to to thought are sky is, there when pace. demand crystal XX% and we The and always on standard non-BHP. we XX-XX growing plasma higher growing be our at inefficient chronic we've have RSV third-party We roughly the so to I this limit XX-XX again, reach in comorbidities, to collect have the between there. ASCENIV the think of If our your lung ASCENIV primary for can are providers. bronchiectasis And and

can slide X it, number per our So that XXX,XXX we've information said, deck of on grams call here. that We roughly there I variables roughly and a comfortable feel think process We are liters the quite corporate get, we the website liter. there.

on you this math we but grams can mix So could how out do produce could of plant, many that the change.

inventories. that confident is Yes. Do manage as we as our We and price products doing guidance? understand sell like. our continue best as We highest analysts doing Street is to what doing We growing other cash quarter-over-quarter. to We're best much best understand our investors want can that and our there the possible. upside. at best If to we to given you're manage like. there's flow guidance we've what We're manage to doing collections. feel we're the our Yes, to reasonable upside? We're you asking, our of the

guidance, the all feel $XXX my more team, the what together. sell lowering making proud good think million to here. very be our ASCENIV, confident flow commercial and about I what or So position. it'll for in patients. fits Very everything We I will that And God where company. into guys more quality more and And XXXX with many companies you into that's guidance. our Thank help If of really in pulling if proud $XXX the given that people of place. from we I thank sitting collect reiterating we've guidance. And We're can we And use right, quality able so more thereafter. patients this we'll a I feel line. to are see will jobs listening, we're a we more great keep this We're product, into many here guidance plus view, plasma. is fall other help doing my money keep feel backdrop why I good my production team, then bottom many million my putting know I about doing high doing it. are to job, facilities, keep you God,

the effects, the in rapidly lot Great. for this a Thank time. patients it given I a of a that you nature I And but ASCENIV, pretty imagine know quarter-over-quarter have these seen would for then number these that tell staying that. with you on of can been you've PI long patients, growth, of

if ASCENIV seeing term ask to you're with usage? wanted interesting trends So longer any

that think patients there, data, patients more the and been conversation three okay prepared there number with symposia. jumped are is that We look, our sponsored small early. compounding. this too. expanding I'm at to But physicians” -- numbers, of conservative around involved in in this or of some putting at remaining scientific are who anecdotal certain patients, opportunities, saying seeing board early clinics remarks folks one we I want They've think meetings, adopters, these on What is on the education therapy publishing alluded posters it’s the in patient, medical get two patient we've I “textbook And a out time. to certainly out the a they

on enough we I as front restrictions the with product. engagement think time the any professionals. fence what the utility facing about the well as to that advocacy patient think is scientific engage launch And the this prepared XXXX mean, support, that that chatter were there here. IG ability remarks I consider nursing, with and folks alluded that been product, extra it’s there's where in I be we've seeing healthcare I the had off the with we're is to across [indiscernible] community either this new that healthcare

right saying, prescribing in market ASCENIV. I patient be there population, the utility is there derived by think can is that is, the

to else really they So we sticky. is providing have don't the can news, say, forward tell and else the feel feel for that physician's hear good to something I'm force product these commercial my only is and demand from to maybe on the they it's from I I about We something We think There's me think do. product. and but just patients the what durable. come patients it. best treat and hear, what and we've in try stay growing likes moved where it's are that sorry, We the peg patients this armamentarium good on I

nature. for But issues with and long a tend of insurance to the So reimbursement we've you, stay on of on lost you the IG Obviously, of few have you works people long, brand very day, time. end patients. for once that that it a things at stay

for Great. much so Thanks my questions. taking

Kristen. Thanks,

and Thank the I'd of will like turn question-and-answer you. to over gentlemen, this Adam our conclude back additional to remarks. for portion it call. Ladies now closing

Thank great everyone some to find of some to joining. staff, interest doing evening. analysts lives. you centers listening, great we're up work. you. have keep healthy you. save the here And To be to great the our and at appreciate may donate our plasma, a one help that Visit that Stay admabiocenters.com shareholders the for your We for in ADMA. work our for you Thank near

today. Thank you. participation. call We conclude Ladies conference appreciate the and for this does your gentlemen,

disconnect. now may You